Develops cancer drugs that target death-receptor 5.
Dec 2025Revenue $1.30M/yrExpenses $136M/yr
No trendCash runway ≈ 1.0 years from Jun 2026
Figures by year
When will Inhibrx Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $1.30M and expenses $136M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.30M | $136M | −$135M |
| Dec 2024 | $200K | $332M | −$331M |
| Dec 2023 | $1.80M | $221M | −$219M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.